Case number 1:24-cv-00698
Amicus Therapeutics US, LLC et al v. Aurobindo Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 31, 2024 | 15 | ORAL ORDER: The Court, having reviewed the parties’ Joint Motion to Consolidate Cases ("Motion"), (D.I. 13 ), hereby ORDERS that the Motion is GRANTED. All papers shall be filed be filed in lead action Civil Action No. 22-1461-CJB. The Protective Order (Civil Action No. 22-1461-CJB (consolidated), D.I. 77), ESI Order (Civil Action No. 22-1461-CJB (consolidated), D.I. 42), and Scheduling Order (Civil Action No. 22-1461-CJB (consolidated), D.I. 29, as amended by D.I. 137) shall govern the consolidated action. Ordered by Judge Christopher J. Burke on 7/31/2024. (smg) (Entered: 07/31/2024) (0) |
| Jul 29, 2024 | 14 | CONSENT to Jurisdiction by U.S. Magistrate Judge filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. Case reassigned to Magistrate Judge Christopher J. Burke. Signed by Judge Colm F. Connolly on 7/29/2024. (nmf) (Entered: 07/29/2024) (1) |
| Jul 29, 2024 | N/A | Remark: The parties should be aware that the Court encourages the participation of newer attorneys in courtroom proceedings and at oral argument. Please see the Court's Standing Order Regarding Courtroom Opportunities for Newer Attorneys, a link to which is provided here for the parties' convenience:http://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrder2017.pdf Associated Cases: 1:24-cv-00696-CJB, 1:24-cv-00698-CJB(smg) (Entered: 07/31/2024) (0) |
| Jul 29, 2024 | N/A | Remark: The parties should follow the Court's Standing Order Regarding Courtesy Copies, a copy of which is found on Judge Burke's portion of the District Court's webpage: https://www.ded.uscourts.gov/sites/ded/files/CJBCC2022.pdf Associated Cases: 1:24-cv-00696-CJB, 1:24-cv-00698-CJB(smg) (Entered: 07/31/2024) (0) |
| Jul 16, 2024 | 13 | Joint MOTION to Consolidate Cases 24-cv-698-CFC into Lead Case No. 22-cv-1461-CJB - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Text of Proposed Order)(Stover, Chad) (Entered: 07/16/2024) (0) |
| Jul 12, 2024 | 12 | ORDER: IT IS ORDERED that, on or before August 12, 2024, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated as to the above cases and, if so, when a joint scheduling conference might most efficiently be conducted. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 8/12/2024.) Signed by Judge Colm F. Connolly on 7/12/2024. Associated Cases: 1:24-cv-00696-CFC, 1:24-cv-00698-CFC(nmf) (Entered: 07/12/2024) (2) |
| Jul 11, 2024 | 10 | ANSWER to 1 Complaint, by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 07/11/2024) (26) |
| Jul 11, 2024 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 07/11/2024) (2) |
| Jun 27, 2024 | 8 | STIPULATION TO EXTEND TIME for Defendants to Answer Complaint to July 11, 2024 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 06/27/2024) (1) |
| Jun 27, 2024 | N/A | SO ORDERED, re 8 STIPULATION TO EXTEND TIME for Defendants to Answer Complaint to July 11, 2024 filed, by Amicus Therapeutics, Inc., Amicus Therapeutics US, LLC. Reset Answer Deadlines: Aurobindo Pharma Ltd. answer due 7/11/2024; Aurobindo Pharma USA, Inc. answer due 7/11/2024. Ordered by Judge Colm F. Connolly on 6/27/2024. (kmd) (Entered: 06/27/2024) (0) |
| Jun 27, 2024 | 9 | STANDING ORDER REGARDING BRIEFING IN ALL CASES. Signed by Judge Colm F. Connolly on 11/10/2022. (kmd) (Entered: 06/27/2024) (2) |
| Jun 18, 2024 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:24-cv-00696-CFC, 1:24-cv-00698-CFC (rjb) (Entered: 06/18/2024) (0) |
| Jun 13, 2024 | 1 | COMPLAINT for PATENT INFRINGEMENT against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. ( Filing fee $ 405, receipt number ADEDC-4429580.) - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(oam) (Entered: 06/14/2024) (0) |
| Jun 13, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) (Entered: 06/14/2024) (3) |
| Jun 13, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: February 16, 2024. Date of Expiration of Patent: January 11, 2042.Thirty Month Stay Deadline: 2/10/2026. (oam) (Entered: 06/14/2024) (3) |
| Jun 13, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,833,164. (oam) (Entered: 06/14/2024) (1) |
| Jun 13, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amicus Therapeutics, Inc. (oam) (Entered: 06/14/2024) (3) |
| Jun 13, 2024 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amicus Therapeutics, Inc. for Amicus Therapeutics US, LLC filed by Amicus Therapeutics US, LLC. (oam) (Entered: 06/14/2024) (3) |
| Jun 13, 2024 | 7 | Summons Issued as to Aurobindo Pharma Ltd. on 6/13/2024; and Aurobindo Pharma USA, Inc. on 6/13/2024. (Attachments: # 1 Summons Issued)(oam) (Entered: 06/14/2024) (0) |
